arrow
T

Tommaso De Pas

istituto clinico humanitas gavazzeni
H指数:43
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Transcriptional evidence of neuroendocrine cell plasticity beyond histological boundaries in lung neuroendocrine neoplasms: an in-silico analysis suggesting a progression model

肺神经内分泌新生物中超越组织学边界的神经内分泌细胞塑性的转录证据:一项提示进展模型的计算机分析

2026-07-280
OA
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials

远处无病生存期作为早期乳腺癌新辅助治疗随机试验中总生存期的替代终点:GBG和AGO-B研究组试验的合并分析

2025-11-240
PRE
Heterogeneity of progression-free survival surrogacy by sex in randomized trials testing immunotherapy in non-small cell lung cancer

非小细胞肺癌免疫治疗随机试验中,按性别划分的无进展生存期代理终点异质性

2025-10-010
OAAI
Sex hormones, the anticancer immune response, and therapeutic opportunities

性激素,抗癌免疫反应和治疗机会

2025-03-011
OAAI
Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis

停用免疫检查点抑制剂的晚期实体瘤患者的结局: 系统回顾和荟萃分析

2024-07-010
OAAI
Clinical recommendations for treatment of localized angiosarcoma: A consensus paper by the Italian Sarcoma Group
2024-05-012
OAAI
Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study (vol 171, pg 183, 2022)
2023-05-010
OAAI
Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a post-hoc analysis
2022-12-083
OAAI
Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study
2022-08-0110
PRE
SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis
2022-05-014
OAAI